Reviewing Hims & Hers Health (NYSE:HIMS) and biote (NASDAQ:BTMD)

Hims & Hers Health (NYSE:HIMS) and biote (NASDAQ:BTMD) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Institutional & Insider Ownership

63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by company insiders. Comparatively, 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Hims & Hers Health and biote, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	1	12	3	0	2.12
biote	1	1	1	1	2.50

Hims & Hers Health currently has a consensus price target of $32.43, suggesting a potential upside of 9.23%. biote has a consensus price target of $2.50, suggesting a potential upside of 140.38%. Given biote’s stronger consensus rating and higher probable upside, analysts clearly believe biote is more favorable than Hims & Hers Health.

Volatility & Risk

Hims & Hers Health has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500. Comparatively, biote has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.

Valuation & Earnings

This table compares Hims & Hers Health and biote”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35 billion	2.95	$128.37 million	($0.63)	-47.13
biote	$192.22 million	0.19	$27.05 million	$0.11	9.45

Hims & Hers Health has higher revenue and earnings than biote. Hims & Hers Health is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Hims & Hers Health and biote’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-5.51%	-6.51%	-1.20%
biote	3.19%	-22.33%	12.10%

Summary

biote beats Hims & Hers Health on 8 of the 15 factors compared between the two stocks.

About Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.